Ciprofloxacin Lactate Sodium Chloride Injection

It has a broad-spectrum antibacterial effect, especially against aerobic Gram-negative rods. It has good antibacterial activity in vitro against the following bacteria: Most bacteria of the Enterobacteriaceae family, including Citrobacter, Enterobacter cloacae, etc. Enterobacter, Escherichia coli, Klebsiella, Proteus, Salmonella, Shigella, Vibrio, Yersinia, etc. It often has antibacterial activity against multi-drug resistant bacteria. It has high antibacterial activity against penicillin-resistant Neisseria gonorrhoeae, enzyme-producing influenza bacilli and Moraxella. It has antibacterial activity against Pseudomonas aeruginosa It has antibacterial activity against most strains of Pseudomonas. It has antibacterial activity against methicillin-sensitive Staphylococcus aureus, and only moderate antibacterial activity against Streptococcus pneumoniae, hemolytic Streptococcus, and Enterococcus faecalis. It has good antimicrobial activity against Chlamydia trachomatis, Mycoplasma, and Legionella, and also has antibacterial activity against Mycobacterium tuberculosis and atypical mycobacteria. It has poor antibacterial activity against anaerobic bacteria. Ciprofloxacin is a bactericide that acts on the A subunit of bacterial DNA helicase to inhibit DNA synthesis and replication, leading to bacterial death.

The main ingredients of this product are: Ciprofloxacin lactate Chemical name: 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7 (1-piperazinyl)-3-quinolinecarboxylic acid lactate Molecular formula: C17H18FN3O3C3H6O3 Molecular weight: 421.43

This product is a colorless or almost colorless clear liquid.

For infections caused by sensitive bacteria: 1. Urinary and reproductive system infections, including simple and complicated urinary tract infections, bacterial prostatitis, urethritis or cervicitis caused by Neisseria gonorrhoeae (including those caused by enzyme-producing strains). 2. Respiratory tract infections, including acute bronchial infections and lung infections caused by sensitive Gram-negative bacilli. 3. Gastrointestinal infections caused by Shigella, Salmonella, enterotoxigenic Escherichia coli, Aeromonas hydrophila, Vibrio parahaemolyticus, etc. 4. Typhoid fever. 5. Bone and joint infections. 6. Skin and soft tissue infections. 7. Systemic infections such as sepsis.

Intravenous drip: 100-200 mg per time, twice a day, diluted in isotonic saline or glucose injection in advance, and the drip time should be no less than 30 minutes.

1 Gastrointestinal reactions are common and may manifest as abdominal discomfort or pain, diarrhea, nausea or vomiting. 2 Central nervous system reactions may include dizziness, headache, drowsiness or insomnia. 3 Allergic reactions: rash, itchy skin, occasionally exudative erythema multiforme and angioneurotic edema. A few patients have photosensitivity reactions. 4 Occasionally, 1. Epileptic seizures, mental abnormalities, irritability, confusion, hallucinations, tremors. 2. Interstitial nephritis manifestations such as hematuria, fever, and rash. 3. Phlebitis. 4. Crystalluria, more common when used in high doses. 5. Joint pain. 5 A small number of patients may experience elevated serum aminotransferase, elevated blood urea nitrogen, and decreased peripheral white blood cells, which are mostly mild and transient.

Patients allergic to ciprofloxacin or other quinolone drugs; children, adolescents, pregnant women and lactating women

Precautions for children: The safety of this product in infants and adolescents under 18 years of age has not been established. However, this product can cause joint lesions when used in several young animals. Therefore, it should not be used in children and adolescents under 18 years of age. Precautions for pregnancy and lactation: Animal experiments have not confirmed that quinolones are teratogenic, but studies on the use of drugs in pregnant women have not yet reached a clear conclusion. Since this drug can cause joint lesions in underage animals, it is contraindicated for pregnant women, and lactating women should suspend breastfeeding when using this product. Precautions for the elderly: Elderly patients often have impaired renal function, and since this product is partially excreted through the kidneys, it needs to be used in reduced doses.

1 Urine alkalinizing agents can reduce the solubility of this product in urine, leading to crystalluria and nephrotoxicity. 2 When this product is used in combination with theophylline, competitive inhibition of the cytochrome P450 binding site may lead to a significant reduction in the liver clearance of theophylline, a prolonged blood elimination half-life, an increase in blood drug concentration, and the appearance of symptoms of theophylline poisoning, such as nausea, vomiting, tremor, restlessness, excitement, convulsions, palpitations, etc. Therefore, theophylline blood drug concentration should be measured and the dose adjusted when used in combination. 3 Cyclosporine combined with this product can increase the blood drug concentration of the former. The blood concentration of cyclosporine must be monitored and the dose adjusted. 4 When this product is used in combination with the anticoagulant warfarin, it can enhance the anticoagulant effect of the latter. When used in combination, the patient's prothrombin time should be closely monitored. 5 Probenecid can reduce the secretion of this product from the renal tubules by about 50%. When used in combination, toxicity may occur due to the increased blood concentration of this product. 6. This product interferes with the metabolism of caffeine, resulting in reduced caffeine clearance, prolonged blood elimination half-life, and possible central nervous system toxicity.

Keep away from light and store in a sealed container.

250ml:0.25g (based on ciprofloxacin)

24 months

Zhejiang Shapuaisi Pharmaceutical Co., Ltd.

• Founded in:

  2000-07-17

• Address:

  No. 1588, Xinming Road, Economic Development Zone, Pinghu City, Zhejiang Province

• Tax NO.:

  91330000146644116H

• Registered Funds:

  375.925005 yuan

• Website:

  Log in to view

• Email:

  Log in to view